

## Decision of the Governing Board of the Innovative Medicines Initiative 2 Joint Undertaking

### Appointing the Members of the IMI2 JU Scientific Committee

THE GOVERNING BOARD OF THE INNOVATIVE MEDICINES INITIATIVE 2 JOINT UNDERTAKING (IMI2 JU),

Having regard to the Statutes annexed to the Council Regulation (EU) No 557/2014 of 7 June 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking and in particular Article 10 thereof;

Having regard to the Rules of Procedure of the Scientific Committee of the IMI2 JU (IMI2/INT/2014-03307) and in particular Articles 2, 5 and 6;

Having regard to the selection process and criteria for the composition of the Scientific Committee approved by the Governing Board on 27 April 2016 (IMI2-GB-DEC-2016-11).

Whereas,

- (1) The Governing Board is responsible for appointing the members of the Scientific Committee and defining which Scientific Committee's advisory documents are to be published on the IMI2 JU website.
- (2) The IMI2 JU States Representatives Group proposed to the Governing Board potential candidate members of the Scientific Committee.
- (3) The Governing Board took into account the candidates proposed considering the criteria established and the availability and willingness of the candidates. It also has considered members in their first mandate that could positively further contribute through a renewal of their mandate.
- (4) The mandate of the Scientific Committee has ended on 30 September 2016, there is a need to appoint members for a new mandate.
- (5) There is also a need to clarify which Scientific Committee's advisory documents are subject to publication.

HAS ADOPTED THE FOLLOWING DECISION:

### Article 1

1. The proposed composition of the IMI2 JU Scientific Committee listed in the annex to this Decision is hereby approved and its members appointed for a period of two years as of 1 October 2016. An additional member from an EU 13 country will be selected before 15 December 2016.
2. Article 6, paragraph 2, of the Rules of Procedure of the Scientific Committee will not apply to contributions or to advice provided by the Scientific Committee members on the scientific priorities as part of the Strategic Research Agenda, of the Annual Work Plan and on the scientific achievements for the Annual Activity Report.

### Article 2

This Decision shall enter into force on the day following its adoption by the Governing Board of the IMI2 JU.

Brussels, on November 7, 2016

For the Governing Board of the Innovative Medicines Initiative 2 JU

  
\_\_\_\_\_  
Marc de Garidel  
Chair of the Governing Board

Annex: List of the Members of the IMI2 JU Scientific Committee

## List of the Members of the IMI2 JU Scientific Committee

## Permanent Members

Name	First name	Country	Gender	Expertise
DA SILVA LIMA	Maria Beatriz	PT	F	Metabolic disorders, Inflammation; Regulatory science
BEKEREDJIAN-DING	Isabelle Béatrice	DE	F	Immunology of infection & Host pathogen interaction; Clinical microbiology and infectious disease
BERNKOP-SCHNÜRCH	Andreas	AT	M	(Oral) drug delivery, nanocarriers, mucoadhesive polymers, peptide delivery, biomaterials, medical devices
BLASCO	Maria	ES	F	Advanced therapies and small molecules, including epigenetic stem cells approaches, preclinical and translational research in various disease areas
CAHILL	Dolores	IE	F	Oncology including immune-oncology combination therapies
CHIOTI	Anna	DK/EL	F	Clinical trials and translational research (Phase I to IV, observational, post marketing); Oncology and personalised medicines (target therapies); Patient Safety & Public health
PEROLA	Markus	FI	M	Epidemiology and public health, metabolic disorders
SCHWEDE	Torsten	CH/DE	M	Bioinformatics & knowledge management
TENSON	Tanel	EE	M	Infectious diseases and antimicrobial resistance
VEZZANI	Annamaria	IT	F	Neuroscience, neurodegenerative disorders, Neuropharmacology

## Ad hoc Member

Name	First name	Country	Gender	Expertise
EICHLER	Hans-Georg	AT	M	Chief Medical Officer at the European Medicines Agency